INTRODUCTION
The receptors from the TNFR family upon their activation by corresponding ligand trigger a number of signaling pathways that regulate diverse biological functions as proliferation, differentiation and also apoptosis 1, 2 . Their common feature of these receptors is the presence of specific structural unit(-s) in their extracellular parts called the cysteine-rich domain (CRD). These approximately 40 amino acids long pseudorepeats contain three disulfide bridges and their interconnecting loops are usually interaction places for their binding to corresponding ligands. A specific group of eight receptors within the TNFR family can be distinguished by the presence of a a-helical protein-protein interaction domain named the Death Domain (DD) 3 . This bundle of six anti-parallel a-helices is an essential platform e.g. for the formation of the Death-Inducing Signaling Complex (DISC), a multiprotein complex required for the proximity-based processing and activation of the initiator caspases-8 and -10. Among the death receptors are both true killers and casual murderers. The killer ones are Fas/CD95 and death domain-containing TRAIL receptors TRAIL-R1/DR4 and TRAIL-R2/DR5. To the later ones belong TNFR1, DR3, DR6, EDAR and NGFR, though EDAR and NGFR upon binding their respective ligands mainly activate signaling pathways connected proliferation, survival and/or differentiation. But even both true killer receptors as Fas/CD95 and DR4/5 receptors can under certain circumstances activate pro-survival and proliferation-related signaling pathways.
TNFR1 -the founding member and a prototypic death receptor
The ligand for TNFR1 receptor (CD120a; p55/60) -Tumour Necrosis Factor (TNF, also known as TNFα) was identified in 1975 as an agent that caused haemorrhagic necrosis of in mice transplanted sarcomas and later cloned and characterized 4, 5 . TNF is expressed as a type II trimeric transmembrane protein, which could be cleaved of by the metalloprotease TNF alpha converting enzyme (TACE) 6, 7 . Both soluble and membrane-bound TNFα upon binding to the cognate receptors TNFR1 (CD120a; p55/60) and TNFR2 (CD120b; p75/80) induce in cellspecific manner pro-survival and pro-inflammatory signaling or cell death. TNFR1 in its extracellular part contains 4 CRDs and the N-terminal Pre-ligand assembly domain (PLAD), which allows formation of pre-assembled receptors at the cell surface 8 . This PLAD domain is also present in other Death receptors as TRAIL-R2 and enhances ligand-mediated activation of these receptors 9 . TNFR1 is widely expressed on most cell types while TNFR2 expression is restricted to hematopoetic cells. As TNFR2 does not contain the death domain, I shall further on focus on TNFR1-triggered signaling and its outcome.
Upon the engagement of either soluble or membranebound TNFα the first TNFR1 signaling complex I is rapidly formed. Its formation and consecutive activation of downstream signaling is greatly enhanced by TNFR1 localization/recruitment to cholesterol-and sphingolipidenriched membrane microdomains, termed lipid rafts 10, 11 . TNFα-induced allosteric changes in the intracellular part of TNFR1 attract a number of adapter proteins and en- Fas/CD95 and TNFR1 upon activation by their cognate ligands multimerize and re-arrange their intracellular parts to form platforms for the formation of multiprotein signaling complexes. TNFR1 signaling complex I is composed of the adapter proteins TRADD, TRAF 2, DD-containing RIP1 kinase and several other associated proteins as cIAP1/2 and E2 protein UBC13. TRAF2 E3 ligase in the complex I then ubiquitinates RIP1 via signaling-related K63 polyubiquitinilation and modified RIP1 then both directly and indirectly (via TAK1 kinase) activates (via IKK kinase complex) phosphorylation and subsequent degradation of IkB and thus activation of NFkB signaling. Complex I activity is negatively regulated by E3 ubiquitin ligases SIAH2, CARP2 and A20 (dual ubiquitin ligase and hydrolase) that target TRAF2 and RIP1 for degradation and by ubiquitin hydrolases CYLD and A20, which remove the signaling K63-linked ubiquitins. Complex I participates also in activation of MAP kinases via yet not fully decrypted pathway and via with TNFR1 DD-interacting riboflavin kinase (RFK) also enhances NADPH oxidase (Nox1/2)-activated production of reactive oxygen species (ROS Ubiquitination of a number of proteins in the complex I plays an important role in the signal transduction in both negative and positive ways and thus it is no wonder that a number of other ubiquitin E3 ligases and hydrolases is associated with and regulates activity of the complex I (reviewed in ref. 12, 13 ). Both TRAFs 2/5 and cIAPs participate in ubiquitination of RIP1, TRAF2 and also TNFR1 via ubiquitin chains linked through lysine 63 (K63) [14] [15] [16] . TRAF2 and combined cIAP1/2 deficiency were shown to abrogate signaling from complex I and sensitize cells from TRAF2 and cIAP1/2 knockout mice to TNFα-mediated apoptosis [15] [16] [17] [18] . K63-linked ubiquitination of RIP1 at K377 is essential for the recruitment and activation of two downstream signaling complexes -the IKK and TAK1 kinases. Polyubiquitinated RIP1 directly recruits IKK complex via the IKK regulatory subunit NEMO and activates IKKα and β kinases in the complex 19, 20 . An alternative indirect route brings the TAK1 complex via its TAB2/3 regulatory, ubiquitin-binding subunits and triggers thus allosteric activation of TAK1 (ref. 21 ). Activated TAK1 then phosphorylates and activates the IKK complex. The activated IkKs then phosphorylates IkBs proteins in the NFkB/ IkB cytosolic complex and marks them for ubiquitination by SCFbTrCP E3 ligase and degradation in the proteasome (reviewed in ref. 22 ). Degradation of IkB proteins releases NFkB heterodimer, which then translocates to the nucleus and activates expression of a number of proinflammatory, anti-apoptotic and also regulatory genes (as A20 or CYLD, see below).
This, so-called canonical pathway of NFkB activation poses a severe implication on the organism and thus needs to be tightly regulated. Similarly as in the activation the complex I-mediated signaling, also in its suppression protein ubiquitination plays an important role. Several E3 ligases and ubiquitin hydrolases compete in shutting down this canonical signaling at the level of the signaling complex I. At least four different proteins were shown to affect ubiquitination of two major constituents of the complex I -RIP1 and TRAF2 (Fig. 1 ). A20 dual E3 ligase and ubiquitin hydrolase was about 10 years ago identified as a critical regulator of TNFα-mediated activation of NFkB 23 . A20 via its ubiquitin hydrolase domain cleaves off activating scaffold K63-linked polyubiquitin chain from RIP1 and subsequently marks RIP1 for proteasomal degradation through its K48-linked polyubiquitination. A20 is also transactivated by NFkB a thus serves as a negative feedback to limit potentially harmful TNFα-induced pro-inflammatory activation of NFkB. A20 activity is enhanced through its interaction with TaxP1, a binding protein of the hTLV Tax protein, its associated E3 ligase Itch a recently also via another interacting protein RFN11 (ref. [24] [25] [26] ). Another two K-48-linking E3 ligases SIAH2 and CARP2 also participate in fine tuning of the NFkB activation pathway. SIAH2 in addition to enhancing the hypoxia response also targets TRAF2 to degradation, thus attenuating activation of NFkB 27, 28 . CARP2 was together with CARP1 identified as Caspase-8-Associated Ring Protein and was reported to attenuate TNFα-induced apoptosis via marking caspase-8 for degradation 29 . It was also recently shown to localize to endosomes and target RIP1 for degradation 30 . In addition to E3 ligases another ubiquitin hydrolase and tumor suppressor -cylindrimatosis (CYLD) negatively influences activation of NFkB via removing the activating K63-linked ubiquitin chain from TRAF2 and is also, similarly as A20, activated by NFkB as a part of autoregulatory feedback loop [31] [32] [33] .
Blocking the NFkB-activating pathway e.g. by suppressing RIP1 ubiquitination shifts a signaling outcome more towards induction of cell death. For TNFα-triggered apoptosis is required endocytosis of the complex I. Then depending on situation several possible cell death-activating complexes II can be formed. Micheau and Tschopp and later Wang et al. documented that TRADD and RIP1 are released from the complex I and form a seeding ground for two cytoplasmic caspase-8-activating complexes IIA (TRADD/FADD/Procaspase-8) and IIB (FADD/ RIP1/Pro-caspase-8) containing in addition adapter protein FADD and pro-caspase-8 (ref. 34, 35 ). However, there is discrepancy when and whether at all these cytoplasmic complexes are formed. In other reports complex II is formed upon RIP1 degradation on internalized TNFR1 endosomes (reviewed in ref. 36 ). Activation of TNFα-induced apoptosis, i.e. formation of the pro-apoptotic complexes II is enhanced by knockout or inactivation of the complex I-activating components RIP1, TRAF2 or cIAPs1/2.
When apoptosis is blocked by suppressing activity of caspases either by endogenous (XIAP) or exogenous caspase inhibitors (e.g. pan-caspase inhibitor zVADfmk or viral proteins as 13R/Spi2 from vaccinia virus) then RIP1-dependent death so called necroptosis can be activated 37, 38 . Essential role of RIP1 kinase activity in the induction of necroptosis was confirmed by blocking necroptosis by necrostatin-1, a specific inhibitor of RIP kinases 39, 40 . From the screening for factors required for necroptosis turned out that in addition to RIP1 also CYLD, BH3-only protein Bmf and other proteins are probably also required 41 . Till recently was still a mystery how exactly can RIP1 activate this necrotic mode of cell death. Apparently the activity of another member of RIP kinase family -RIP3 was also required in this process 42 . Recent discoveries from 3 groups now bring at least some light to deciphering this necrotic pathway 38, 43, 44 . They all document that RIP3 kinase (in addition to RIP1) is essential for the activation of TNFa-induced necroptosis. Both complexes IIA and IIB could upon RIP3 binding, and when caspase-dependent apoptotic pathway is blocked, transit from the pro-apoptotic to the pro-necrotic signaling. RIP3 kinase activity is essential for this transition and blocking its activity with necrostatin-1 suppresses interaction between RIP1/3 and FADD as well as RIP1-RIP3 association. FADD seems to be important but not entirely essential for RIP1/3 phosphorylation activity as RIP1 phosphorylation still takes place in FADD-deficient Jurkat cells 38 . One of the necrotic death tools are also ROS that are required for TNFα-activated necroptosis in L929 cells 37 . Interestingly RIP3 in the necroptosis-activating complexes interacts with several enzymes that could affect production of ROS, namely with glycogen phosphorylase (PYGL), glutamate ammonia ligase (GLUL), and glutamate dehydrogenase 1 (GLUD1) 44 and enhances their enzymatic activities. These and other identified metabolism-related enzymes indirectly affect oxidative phosphorylation in mitochondria and thus also the production of mitochondrial ROS. Their siRNA-mediated knockdown partially protected NIH3T3 cells against TNFα/zVAD-induced necroptosis. However, they seems to be just hijacked by the necroptosis apparatus as their physiological function (similarly as that of RIP3) is to provide energy to cells that underwent through some toxic insult or injury.
The fate of the first death receptor underwent an interesting evolution from its discovery about 30 years ago -from mainly pro-inflammatory to apoptosis-inducing receptor with recently the circle closing and TNFR1 stands its true name as under specific circumstances the necrosis or better necroptosis-inducing one.
The deadly siblings -Fas/CD95 and TRAIL receptors
Receptors for the cytotoxic ligands FasL and TRAIL were discovered in the last decade of the past century either as targets of apoptosis-inducing monoclonal antibodies (Fas/CD95) or similarly as the TRAIL ligand by computer-aided cloning (TRAIL-Rs) [45] [46] [47] [48] . In addition to two pro-apoptotic, death domain-containing TRAIL receptors TRAIL-R1/DR4 and TRAIL-R2/DR5 were in human cells discovered three additional so-called decoy receptors, membrane-bound TRAIL-R3/DcR1, TRAIL-R4/DcR2 and soluble osteoprotegerin. Similar decoy, inhibitory receptor DcR3 was also identified for the FasL 49 . When overexpressed, these decoy receptors suppress signaling, mainly induction of apoptosis, from the DD-containing receptors. Fas/CD95 and DD-containing TRAIL receptors are expressed on majority of normal cells but their ligands are under normal conditions expressed on hematopoietic cells (mainly T lymphocytes and NK cells).
Upon activation with the membrane-bound (FasL, TRAIL) or soluble (agonistic antibodies, recombinant TRAIL or recombinant and multimerized FasL) ligands the DD-containg receptors are trimerized/multimerized and form an accepting platform for binding the additional components of DISC -the adapter protein FADD and pro-caspases-8/10 (reviewed in ref. 36, 50 ). In a sharp contrast to TNFR1-activated signaling, the activated Fas/CD95 or TRAIL receptors predominantly activate apoptosis and not the inflammatory response via NFkB activation. Through homotypic aggregation in DISC, enhanced by low levels of the inactive cFLIP L , originally a competitive inhibitor of caspase-8 activation, caspase-8 is gradually activated and released into cytosol, where it cleaves its target proteins, most notably the pro-apoptotic, BH3-only protein Bid 51 . In contrast to TRAIL receptors, which could be apparently fully activated at the cytoplasmic membrane, efficient activation of Fas/CD95 DISC and subsequently caspase-8 requires receptor internalization via mainly clathrin-dependent endocytosis 36, 52, 53 . Furthermore and also in a contrast to TNFR1, postranslational modifications of these receptors such as S-linked palmitoylation of membrane-proximal cysteines or O-linked glycosylation of the extracellular parts of TRAIL receptors enhance their aggregation, mainly in lipid rafts, and subsequently the efficacy of the DISC activation and caspase-8 selfprocessing [52] [53] [54] [55] . More or less efficient activation of the initiator caspase-8 and the presence (or absence) of intracellular inhibitors of apoptosis from the Bcl-2 or IAP families then sends affected cell to so-called type I or type II of the apoptotic signaling [56] [57] [58] [59] . An essential transducer of the apoptotic signaling in type II cells as hepatocytes is the BH3-only protein Bid 60 . Activated caspase-8 cleavesoff N-terminal part of Bid, allowing it then to undergo N-terminal myristoylation together with unmasking of its BH3 domain and then its efficient transport to mitochondria 61 . In mitochondria the activated Bid can both target and inactivate anti-apoptotic Bcl-2, such as Bcl-2 itself, Bcl-X L or Mcl1, as well as directly interact with the pro-apoptotic Bax or Bak proteins and accelerate thus their oligomerization a formation of channels in the outer mitochondrial membrane [62] [63] [64] [65] . Permeabilized mitochondria then release a cavalry of pro-apoptotic proteins from cristae and the inter-membrane space such as cytochrome c, endonucleases AIF and endoG as well as Smac/DIABLO and HrtA2/Omi, competitive inhibitors of anti-apoptotic proteins from the IAP family (reviewed in ref. 66 ). Concerned action of these proteins ensures amplification of the apoptotic signal and dooms a fate of the affected cells. Interestingly an alternative way of caspase-8 activation in Fas-induced apoptosis of type II cells was recently proposed by Gonzalves et al. 67 . In this scenario a mitochondria-specific phospholipid cardiolipin serves as a platform for full processing and activation of caspase-8.
Both FasL-and TRAIL-induced apoptosis are important effectors as well as regulators of the immune system 68, 69 . Fas-mediated killing is together with granzyme/ perforin system used by the cytotoxic T cells for both elimination of target e.g. damaged or transforming cells as well as, together with BH3-only protein Bim-induced apoptosis, for maintaining of T cell homeostasis 70 . Also TRAIL-mediated apoptosis is implicated both in NK cells-mediated killing of tumor, preferentially metastatic cells and in the maintenance of the immune system through TRAIL-induced elimination of "helpless" CD8+ T cells 71, 72 . In addition to the induction of apoptosis both Fas/CD95 and TRAIL receptors have been under certain circumstance implicated in activation of non-apoptotic signaling mediated via NFkB and MAP kinases pathways as well as, similarly as TNFR1, in inducing a necrosis-like mode of death. RIP1 kinase and the caspase-8 competitive inhibitor FLIP L are implicated in the formation secondary cytoplasmic complexes that transduce both necrotic and Signaling activated by the death receptors of the TNFR family pro-survival signaling 3, 73 . Interestingly, Fas/CD95 stimulation on the native T cells neither induces apoptosis (in a contrast to activated T cells), nor pro-survival pathways but efficiently suppresses their proliferation through yet undefined mechanism that prevents translocation of important signaling proteins as ZAP-70 or phospholipase γ into lipid rafts 74 . In addition to its physiological role, TRAIL-induced signaling could one of the important tools in our fight against cancer. Unique feature of TRAIL-induced apoptosis is its prevalence against transformed cells while sparing the normal ones 75 . Both the recombinant ligand and the agonistic anti-DR4 or DR5 humanized monoclonal antibodies are currently in phase I/II of clinical trials as mono-ore combi-therapeutics against many types of tumors 76, 77 .
Other members of the death domain group -ambiguous receptors with the death domain
In contrast the founding member of this family, TNFR1 and two fundamentally pro-apoptotic FasL-or TRAIL-induced signaling, other receptors from the DD group have more diverge functions.
EDAR (ectodysplasin A receptor) was cloned by positional cloning of gene/-s mutated in downless (dl) mice that suffer with defects in hair follicles, lack sweat glands and have malformed teeth 78 . Defects in EDAR signaling are manifested in a rare and life-threatening human disorder X-linked hypohidrotic diaplasia caused by mutations in Eda gene on X chromosome. At least in mice this phenotype can be cured by the treatment of pregnant mice with the recombinant ligand EDA1 (ref. 79 ). Despite its death domain, ligation of EDAR with EDA1 does not induce apoptosis, but via a novel death domain-containing adapter crinkled (CR) it activates canonical NFkB signaling pathway regulated by already mentioned ubiquitin hydrolase cylidrimatosis 80, 81 . Widely expressed NGF receptor or p75 neurotrophin receptor possesses so-called type II death domain apparently different from the other members of the death domain subfamily. Also, in addition to NGF, NGFR interacts with other ligands as BDNF or neurotrophins. Activated NGFR heterodimerizes with TrkA co-receptor and via triggering a number of signaling pathways (MAP kinases, PI-3 kinase and NFkB) grants neuronal proliferation and survival (reviewed in ref. 82, 83 ). Similarly as other death receptors, NGFR can also transduce cell death signaling under certain conditions. When activated either by BDNF or neurotrophins without co-stimulatory signaling from TrkA, NGFR can via enhanced ceramide production and activation of JNK and p38 MAPK pathways trigger apoptosis in oligodendrocytes or in stressed hippocampal neurons 84, 85 . Another two death domain-containing receptors Death Receptor 3 (DR3) and Death Receptor 6 (DR6) were originally identified by homology cloning and for a long time remained as orphan receptors 86, 87 . Both of them also upon transient overexpression induced weak apoptosis in some tumor-derived cell lines through yet undefined mechanism, but their main signaling proceeds via activation of NFkB and MAP kinases (mainly JNK and p38) transduction pathways. TL1A (TNF-like factor 1) was then identified as the major DR3 ligand and via NFkB activation functions as T cell activation co-stimulator 88 . DR3 has a prominent role in the regulation of the immune system as it contributes to efficient T cell activation, mainly during inflammatory response 89, 90 . However, in non-hematopoiteic cells DR3 apparently plays also an active role in the development of antigen-induced arthritis (AIA) and contributes to human renal tubular epithelial cells (TEC) destruction in response to injury 91, 92 . DR6, another highly glycosylated 93 and till this year an orphan receptor is expressed both on hematopoietic and neuronal cells. Phenotype of DR6 knockout mice also suggests involvement of DR6 in the regulation of the immune response. Both CD4+ T and B lymphocytes from DR6-/-mice hyperproliferate and grafted DR6-/-T cells trigger accelerated and more severe graft-vs-host disease (GVHD) [94] [95] [96] [97] . Despite the pronounced hematopoietic phenotype, discovery of the DR6 ligand came from the neuronal shore. Through functional screening Nikolaev et al. 98 uncovered that DR6 is required both for death of neuronal bodies as well as for axon pruning and its long-sought ligand is the N-terminal, cleaved-off part of beta-amyloid precursor protein (APP). N-APP-mediated activation of DR6 triggers caspase-3-dependent one apoptosis in cell bodies and caspase-6-dependent in axons. Homologous APLP2, which is expressed on monocytes and dendritic cells, could serve as a ligand for DR6 expressed on activated CD4+ T cells (M. Klima, unpublished data).
Conclusions and perspectives
The death receptors of the TNFR family are distinguished from the other membrane receptors not only by their specific structural features but mainly by their among membrane receptors very specific function of inducing cell death via both apoptotic and necrotic signaling pathways. The main representatives of pro-death signaling from this group TNFR1, Fas/CD95 and DD-containing TRAIL receptors in the initial stages of pro-apoptotic signaling form multiprotein complexes that serve as activating platforms either for efficient processing of the initiator caspases-8 and -10 or later on for the transduction of necrotic RIP kinases-mediated signaling. However, the induction of cell death is not the only function of these multitask membrane receptors. Under some circumstance they do induce pro-proliferative and pro-inflammatory response (the main feature of TNFR1-activated signaling) via activation of NFkB and MAP kinases pathways. Unique tumor cells-biased attribute of TRAIL-induced apoptosis is at the presence being exploited therapeutically, and sparks a hope for more efficient and targeted tumor therapy. However, despite significant accumulation of knowledge about the signaling pathways activated by these receptors and their physiological outcomes we still miss important data about regulation of their signaling or their communication with other signaling pathways and thus many of these secrets just "eagerly" wait for being, hopefully in a near future, uncovered. 
